❉ Buffybot wonderful businesses, fair prices

← back

IQV IQVIA

pharma · 2026-10-22

N/A
too hard · 56
Owner-earnings value$170.19
Price$276.63
Margin of safety -38.5%

Quality gate · 56/100

Returns on capital 7.8/30
Consistency 21.2/22
Margins / pricing power 9.7/16
Balance sheet 1.6/16
Cash conversion 10/10
Capital allocation 5.8/6

⚠ sub-hurdle returns (median roic 9% < 9%)

Median ROIC8.9%
Gross margin33.0%
Net debt / EBITDA4.0x
FCF conversion140%
Share count / yr-3.0%
Profitable years4/4

Moat & management

Owner-earnings inputs

Owner earnings (TTM)1.92B
Owner-earnings yield4.2%
Free-cash-flow yield4.8%
Growth used (normalized)4.2%
Market-implied growth (reverse DCF)16.4%
Terminal growth3.0%
Discount rate (hurdle)10.4%

Projected owner earnings

YrOwner earningsGrowthPV
12.00B 4.2%1.81B
22.09B 4.1%1.71B
32.17B 3.9%1.61B
42.25B 3.8%1.51B
52.33B 3.7%1.42B
62.42B 3.5%1.33B
72.50B 3.4%1.25B
82.58B 3.3%1.17B
92.66B 3.1%1.09B
102.74B 3.0%1.02B

⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~16%/yr owner-earnings growth over 10y (reverse DCF); model credits 4%.

History

DateQualityPriceValueMoSRating
2026-10-22 56 $276.63 $170.19 -38.5% N/A
2026-09-18 56 $269.44 $173.60 -35.6% N/A
2026-08-18 56 $241.24 $181.13 -24.9% N/A
2026-07-16 58 $206.81 $183.46 -11.3% N/A
2026-07-02 58 $203.20 $183.53 -9.7% N/A
2026-06-25 58 $185.62 $185.49 -0.1% N/A
2026-06-23 58 $171.28 $183.05 +6.9% N/A